Search

Your search keyword '"Janjigian Y"' showing total 137 results
Start Over Author "Janjigian Y"
137 results on '"Janjigian Y"'

2. SO-6 Novel frailty index predicts short-term outcomes after esophagectomy in elderly patients with esophageal cancer

Author

Boerner, T., primary, Tin, A., additional, Vickers, A., additional, Harrington, C., additional, Janjigian, Y., additional, Ilson, D., additional, Wu, A., additional, Bott, M., additional, Isbell, J., additional, Park, B., additional, Sihag, S., additional, Jones, D., additional, Downey, R., additional, Shahrokni, A., additional, and Molena, D., additional

Published
2022
Full Text
View/download PDF

3. SO-7 Co-occurring HER2 and PD-L1 expression in patients with HER2-positive trastuzumab-refractory gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): Biomarker analysis from the trastuzumab deruxtecan (T-DXd) DESTINY-Gastric03 trial

Author

Janjigian, Y., primary, Rha, S., additional, Oh, D., additional, Díez García, M., additional, van Laarhoven, H., additional, Chao, Y., additional, Di Bartolomeo, M., additional, Haj Mohammad, N., additional, Zhong, W., additional, Croydon, E., additional, Cecchi, F., additional, and Lee, J., additional

Published
2022
Full Text
View/download PDF

4. P-156 MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma: Trial in progress

Author

Tabernero, J., primary, Strickler, J., additional, Nakamura, Y., additional, Shitara, K., additional, Janjigian, Y., additional, Barzi, A., additional, Bekaii-Saab, T., additional, Lenz, H., additional, Yoshino, T., additional, Siena, S., additional, Garrido-Mayor, J., additional, Ubowski, M., additional, Xie, D., additional, and Marshall, J., additional

Published
2022
Full Text
View/download PDF

7. Quality of life with first-line pembrolizumab for PD-L1epositive advanced gastric/gastroesophageal junction adenocarcinoma: results from the randomised phase III KEYNOTE-062 study

Author

Van Cutsem, E., Valderrama, A., Bang, Yung-Jue, Fuchs, C. S., Shitara, Kohei, Janjigian, Y. Y., Qin, S., Larson, T. G., Shankaran, V., Stein, S., Norquist, J. M., Kher, U., Shah, S., Alsina, Maria, Universitat Autònoma de Barcelona, Institut Català de la Salut, [Van Cutsem E] Department of Digestive Oncology, University Hospital Gasthuisberg Leuven and KU Leuven, Leuven, Belgium. [Valderrama A] Center for Observational and Real-World Evidence, Merck & Co., Inc., Kenilworth, USA. [Bang YJ] Department of Biomedical Research, Seoul National University College of Medicine, Seoul, South Korea. [Fuchs CS] Department of Internal Medicine: Hematology, Medical Oncology, Gastro-oncology, Yale University Cancer Center, Smilow Cancer Hospital, New Haven, USA. [Shitara K] Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan. [Janjigian YY] Department of Gastrointestinal Oncology, Medicine, Memorial Sloan Kettering Cancer Center, New York, USA. [Alsina M] Servei d’Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain, and Vall d'Hebron Barcelona Hospital Campus

Subjects
Cancer Research, Abdominal pain, medicine.medical_specialty, Nausea, medicine.medical_treatment, Population, Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], Pembrolizumab, Adenocarcinoma, Other subheadings::Other subheadings::/drug therapy [Other subheadings], Antibodies, Monoclonal, Humanized, Gastroenterology, Esòfag - Càncer - Tractament, B7-H1 Antigen, gastroesophageal cancer, Quality of life, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, education, Original Research, Chemotherapy, education.field_of_study, business.industry, gastric cancer, Neoplasms::Neoplasms by Histologic Type::Neoplasms, Glandular and Epithelial::Carcinoma::Adenocarcinoma [DISEASES], Hazard ratio, neoplasias::neoplasias por tipo histológico::neoplasias glandulares y epiteliales::carcinoma::adenocarcinoma [ENFERMEDADES], social sciences, humanities, Adenocarcinoma - Tractament, Oncology, quality of life, patient-reported outcomes, Vomiting, Digestive System::Gastrointestinal Tract::Upper Gastrointestinal Tract::Esophagus::Esophagogastric Junction [ANATOMY], sistema digestivo::tracto gastrointestinal::tracto gastrointestinal superior::esófago::unión esofagogástrica [ANATOMÍA], Esophagogastric Junction, pembrolizumab, medicine.symptom, business
Abstract

Background In the randomised phase III KEYNOTE-062 study, pembrolizumab was non-inferior to chemotherapy for overall survival in patients with programmed death-ligand 1 (PD-L1)-positive [combined positive score (CPS) ≥1] advanced gastric/gastroesophageal junction (GEJ) cancer. We present findings of prespecified health-related quality-of-life (HRQOL) analyses for pembrolizumab versus chemotherapy in this population. Materials and methods HRQOL, a secondary endpoint, was measured in patients who received ≥1 dose of study treatment and completed ≥1 HRQOL questionnaire [European Organisation for the Research and Treatment of Cancer (EORTC) 30-question quality-of-life (QLQ-C30), EORTC 22-question quality-of-life gastric-cancer-specific module (QLQ-STO22)]. Least squares mean (LSM) change (baseline to week 18) in global health status/quality of life (GHS/QOL; EORTC QLQ-C30) and time to deterioration (TTD) in GHS/QOL, nausea/vomiting and appetite loss scores (EORTC QLQ-C30) and abdominal pain/discomfort scores (EORTC QLQ-STO22) were evaluated. Results The HRQOL population comprised 495 patients with CPS ≥1 (pembrolizumab, 252; chemotherapy, 243). Compliance rates at week 18 were similar for pembrolizumab and chemotherapy (EORTC QLQ-C30, 87.9% and 81.9%; EORTC QLQ-STO22, 87.9% and 81.3%, respectively). There was no between-arm difference in LSM score change in GHS/QOL [−0.16; 95% confidence interval (CI) −5.01 to 4.69; P = 0.948]. The LSM score change for most subscales showed comparable worsening in both arms. TTD for GHS/QOL [hazard ratio (HR), 0.96; 95% CI, 0.67-1.38; P = 0.826], appetite loss (HR, 0.83; 95% CI, 0.58-1.20; P = 0.314) and pain (HR, 1.22; 95% CI, 0.78-1.91; P = 0.381) were similar between arms. Longer TTD was observed for pembrolizumab versus chemotherapy for nausea/vomiting (HR, 0.61; 95% CI, 0.44-0.85; P = 0.003). Conclusions HRQOL was maintained with first-line treatment with pembrolizumab in patients with PD-L1–positive advanced gastric/GEJ cancer and was similar between pembrolizumab and chemotherapy in this population., Highlights • HRQOL was similar between pembrolizumab and chemotherapy in patients with PD-L1-positive advanced gastric/GEJ cancer. • General HRQOL as measured by QLQ-C30 GHS/QOL scores was comparable between treatment arms from baseline to week 18. • The EQ-5D-3L visual analogue scale was also equivalent between arms from baseline to week 18.

Published
2021

8. Prognosis after neoadjuvant chemoradiation or chemotherapy for locally advanced gastro-oesophageal junctional adenocarcinoma

Author

Vos, E L, primary, Carr, R A, additional, Hsu, M, additional, Nakauchi, M, additional, Nobel, T, additional, Russo, A, additional, Barbetta, A, additional, Tan, K S, additional, Tang, L, additional, Ilson, D, additional, Ku, G Y, additional, Wu, A J, additional, Janjigian, Y Y, additional, Yoon, S S, additional, Bains, M S, additional, Jones, D R, additional, Coit, D, additional, Molena, D, additional, and Strong, V E, additional

Published
2021
Full Text
View/download PDF

9. P-174 MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma: Trial in progress

Author

Strickler, J., primary, Nakamura, Y., additional, Shitara, K., additional, Catenacci, D., additional, Janjigian, Y., additional, Barzi, A., additional, Bekaii-Saab, T., additional, Lenz, H., additional, Lee, J., additional, Van Cutsem, E., additional, Chung, H., additional, Tabernero, J., additional, Yoshino, T., additional, Siena, S., additional, Garrido-Mayor, J., additional, Palanca-Wessels, M., additional, Xie, D., additional, and Marshall, J., additional

Published
2021
Full Text
View/download PDF

10. LBA-4 Initial data from the phase 3 KEYNOTE-811 study of trastuzumab and chemotherapy with or without pembrolizumab for HER2-positive metastatic gastric or gastroesophageal junction (G/GEJ) cancer

Author

Janjigian, Y., primary, Kawazoe, A., additional, Weber, P., additional, Luo, S., additional, Lonardi, S., additional, Kolesnik, O., additional, Barajas, O., additional, Bai, Y., additional, Shen, L., additional, Tang, Y., additional, Wyrwicz, L., additional, Shitara, K., additional, Qin, S., additional, Van Cutsem, E., additional, Tabernero, J., additional, Li, L., additional, Shih, C., additional, Bhagia, P., additional, and Chung, H., additional

Published
2021
Full Text
View/download PDF

11. P-63 MATTERHORN: A phase 3 study of efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer

Author

Janjigian, Y., primary, Van Cutsem, E., additional, Muro, K., additional, Wainberg, Z., additional, Al-Batran, S., additional, Hyung, W., additional, Molena, D., additional, Evans, B., additional, Ruscica, D., additional, Robbins, S., additional, Negro, A., additional, and Tabernero, J., additional

Published
2021
Full Text
View/download PDF

12. O-5 Frequency of minimal residual disease as measured by ctDNA in mismatch repair deficient tumors following curative resection

Author

Janjigian, Y., primary, Lumish, M., additional, Jayakumaran, G., additional, Fox, M., additional, Sabwa, S., additional, Cercek, A., additional, Stadler, Z., additional, Ku, G., additional, Segal, N., additional, Won, E., additional, Maron, S., additional, Troso-Sandoval, T., additional, Segal, M., additional, Strong, V., additional, Molena, D., additional, Weiser, M., additional, Jones, D., additional, Zehir, A., additional, Berger, M., additional, and Diaz, L., additional

Published
2021
Full Text
View/download PDF

13. P-154 A randomized phase 3 study evaluating the efficacy and safety of first-line pembrolizumab plus lenvatinib plus chemotherapy compared with chemotherapy in patients with advanced/metastatic gastroesophageal adenocarcinoma: LEAP-015

Author

Tabernero, J., primary, Cohen, D., additional, Van Cutsem, E., additional, Janjigian, Y., additional, Bang, Y., additional, Qin, S., additional, Wang, A., additional, Hawk, N., additional, Shih, C., additional, Bhagia, P., additional, and Shitara, K., additional

Published
2021
Full Text
View/download PDF

25. KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer: a double-blind, randomized, placebo-controlled phase 3 study

Author

Chung, H., primary, Bang, Y., additional, Fuchs, C., additional, Qin, S., additional, Satoh, T., additional, Shitara, K., additional, Tabernero, J., additional, Van Cutsem, E., additional, Cao, Z., additional, Chen, X., additional, Kang, S., additional, Shih, C., additional, and Janjigian, Y., additional

Published
2019
Full Text
View/download PDF

27. Poor survival after resection of early gastric cancer: extremes of survivorship analysis reveal distinct genomic profile.

Author

Datta, J., Da Silva, E. M., Kandoth, C., Song, T., Russo, A. E., Hernandez, J. M., Taylor, B. S., Janjigian, Y. Y., Tang, L. H., Solit, D. B., and Strong, V. E.

Subjects
STOMACH cancer, GASTRECTOMY, CANCER relapse
Abstract

A subset of patients with early gastric cancer demonstrate early recurrence and poor survival despite margin-negative resection. Although the frequency of I TP53 i hotspots and I TP53 i LOH did not vary statistically significantly across cohorts, co-altered I TP53 i SP MUT/LOH sp remained more prevalent in the MSK-EGC1 cohort than in the MSK-EGC2 or MSK-LAGC1 cohorts (5 of 10 I versus i 1 of 10 I versus i 1 of 10 respectively; I P i = 0-151) ( I Fig i . When pooling the extremes-of-survivorship cohorts (40 patients), those with I TP53 i SP MUT/LOH sp tumours demonstrated significantly worse DSS than patients with tumours without I TP53 i SP MUT/LOH sp (median 32-5 months I versus i not reached respectively; I P i = 0-018) ( I Fig i . [Extracted from the article]

Published
2020
Full Text
View/download PDF

29. Integrated genomic characterization of oesophageal carcinoma

Author

Kim, J, Bowlby, R, Mungall, AJ, Robertson, AG, Odze, RD, Cherniack, AD, Shih, J, Pedamallu, CS, Cibulskis, C, Dunford, A, Meier, SR, Raphael, BJ, Wu, H-T, Wong, AM, Willis, JE, Bass, AJ, Derks, S, Garman, K, McCall, SJ, Wiznerowicz, M, Pantazi, A, Parfenov, M, Thorsson, V, Shmulevich, I, Dhankani, V, Miller, M, Sakai, R, Wang, K, Schultz, N, Shen, R, Arora, A, Weinhold, N, Sanchez-Vega, F, Kelsen, DP, Zhang, J, Felau, I, Demchok, J, Rabkin, CS, Camargo, MC, Zenklusen, JC, Bowen, J, Leraas, K, Lichtenberg, TM, Curtis, C, Seoane, JA, Ojesina, AI, Beer, DG, Gulley, ML, Pennathur, A, Luketich, JD, Zhou, Z, Weisenberger, DJ, Akbani, R, Lee, J-S, Liu, W, Mills, GB, Zhang, W, Reid, BJ, Hinoue, T, Laird, PW, Shen, H, Piazuelo, MB, Schneider, BG, McLellan, M, Taylor-Weiner, A, Lawrence, M, Cibulskis, K, Stewart, C, Getz, G, Lander, E, Gabriel, SB, Ding, L, McLellan, MD, Miller, CA, Appelbaum, EL, Cordes, MG, Fronick, CC, Fulton, LA, Mardis, ER, Wilson, RK, Schmidt, HK, Fulton, RS, Ally, A, Balasundaram, M, Carlsen, R, Chuah, E, Dhalla, N, Holt, RA, Jones, SJM, Kasaian, K, Brooks, D, Li, HI, Ma, Y, Marra, MA, Mayo, M, Moore, RA, Mungall, KL, Schein, JE, Sipahimalani, P, Tam, A, Thiessen, N, Wong, T, Beroukhim, R, Bullman, S, Murray, BA, Saksena, G, Schumacher, SE, Gabriel, S, Meyerson, M, Hadjipanayis, A, Kucherlapati, R, Ren, X, Park, PJ, Lee, S, Kucherlapati, M, Yang, L, Baylin, SB, Hoadley, KA, Bootwalla, MS, Lai, PH, Van den Berg, DJ, Berrios, M, Holbrook, A, Hwang, J-E, Jang, H-J, Weinstein, JN, Lu, Y, Sohn, BH, Mills, G, Seth, S, Protopopov, A, Bristow, CA, Mahadeshwar, HS, Tang, J, Song, X, Cho, J, Defrietas, T, Frazer, S, Gehlenborg, N, Heiman, DI, Lawrence, MS, Lin, P, Noble, MS, Doug, V, Zhang, H, Polak, P, Chin, L, Bernard, B, Iype, L, Reynolds, SM, Abeshouse, A, Armenia, J, Kundra, R, Ladanyi, M, Kjong-Van, L, Gao, J, Sander, C, Chakravarty, D, Radenbaugh, A, Hegde, A, Penny, R, Crain, D, Gardner, J, Curley, E, Mallery, D, Morris, S, Paulauskis, J, Shelton, T, Shelton, C, Frick, J, Gastier-Foster, JM, Gerken, M, Leraas, KM, Ramirez, NC, Wise, L, Zmuda, E, Tarvin, K, Saller, C, Park, YS, Button, M, Carvalho, AL, Reis, RM, Matsushita, MM, Lucchesi, F, de Oliveira, AT, Le, X, Paklina, O, Setdikova, G, Lee, J-H, Bennett, J, Iacocca, M, Huelsenbeck-Dill, L, Potapova, CO, Voronina, O, Liu, O, Fulidou, V, Cates, C, Sharp, A, Behera, M, Force, S, Khuri, F, Owonikoko, T, Pickens, A, Ramalingam, S, Sica, G, Dinjens, W, van Nistelrooij, A, Wijnhoven, B, Sandusky, G, Stepa, S, Juhl, IH, Zornig, C, Kwon, SY, Kelsen, D, Kim, GHK, Bartlett, J, Parfitt, J, Chetty, R, Darling, G, Knox, J, Wong, R, El-Zimaity, H, Liu, G, Boussioutas, A, Park, DY, Kemp, R, Carlotti, CG, da Cunha Tirapelli, DP, Saggioro, FP, Sankarankutty, AK, Noushmehr, H, dos Santos, JS, Trevisan, FA, Eschbacher, J, Dubina, M, Mozgovoy, E, Carey, F, Chalmers, S, Forgie, I, Godwin, A, Reilly, C, Madan, R, Naima, Z, Ferrer-Torres, D, Rathmell, WK, Dhir, R, Luketich, J, Ajani, JA, Janjigian, Y, Tang, L, Cheong, J-H, Chudamani, S, Liu, J, Lolla, L, Naresh, R, Pihl, T, Sun, Q, Wan, Y, Wu, Y, Demchok, JA, Ferguson, ML, Shaw, KRM, sheth, M, Tarnuzzer, R, Wang, Z, Hutter, CM, Sofia, HJ, Kim, J, Bowlby, R, Mungall, AJ, Robertson, AG, Odze, RD, Cherniack, AD, Shih, J, Pedamallu, CS, Cibulskis, C, Dunford, A, Meier, SR, Raphael, BJ, Wu, H-T, Wong, AM, Willis, JE, Bass, AJ, Derks, S, Garman, K, McCall, SJ, Wiznerowicz, M, Pantazi, A, Parfenov, M, Thorsson, V, Shmulevich, I, Dhankani, V, Miller, M, Sakai, R, Wang, K, Schultz, N, Shen, R, Arora, A, Weinhold, N, Sanchez-Vega, F, Kelsen, DP, Zhang, J, Felau, I, Demchok, J, Rabkin, CS, Camargo, MC, Zenklusen, JC, Bowen, J, Leraas, K, Lichtenberg, TM, Curtis, C, Seoane, JA, Ojesina, AI, Beer, DG, Gulley, ML, Pennathur, A, Luketich, JD, Zhou, Z, Weisenberger, DJ, Akbani, R, Lee, J-S, Liu, W, Mills, GB, Zhang, W, Reid, BJ, Hinoue, T, Laird, PW, Shen, H, Piazuelo, MB, Schneider, BG, McLellan, M, Taylor-Weiner, A, Lawrence, M, Cibulskis, K, Stewart, C, Getz, G, Lander, E, Gabriel, SB, Ding, L, McLellan, MD, Miller, CA, Appelbaum, EL, Cordes, MG, Fronick, CC, Fulton, LA, Mardis, ER, Wilson, RK, Schmidt, HK, Fulton, RS, Ally, A, Balasundaram, M, Carlsen, R, Chuah, E, Dhalla, N, Holt, RA, Jones, SJM, Kasaian, K, Brooks, D, Li, HI, Ma, Y, Marra, MA, Mayo, M, Moore, RA, Mungall, KL, Schein, JE, Sipahimalani, P, Tam, A, Thiessen, N, Wong, T, Beroukhim, R, Bullman, S, Murray, BA, Saksena, G, Schumacher, SE, Gabriel, S, Meyerson, M, Hadjipanayis, A, Kucherlapati, R, Ren, X, Park, PJ, Lee, S, Kucherlapati, M, Yang, L, Baylin, SB, Hoadley, KA, Bootwalla, MS, Lai, PH, Van den Berg, DJ, Berrios, M, Holbrook, A, Hwang, J-E, Jang, H-J, Weinstein, JN, Lu, Y, Sohn, BH, Mills, G, Seth, S, Protopopov, A, Bristow, CA, Mahadeshwar, HS, Tang, J, Song, X, Cho, J, Defrietas, T, Frazer, S, Gehlenborg, N, Heiman, DI, Lawrence, MS, Lin, P, Noble, MS, Doug, V, Zhang, H, Polak, P, Chin, L, Bernard, B, Iype, L, Reynolds, SM, Abeshouse, A, Armenia, J, Kundra, R, Ladanyi, M, Kjong-Van, L, Gao, J, Sander, C, Chakravarty, D, Radenbaugh, A, Hegde, A, Penny, R, Crain, D, Gardner, J, Curley, E, Mallery, D, Morris, S, Paulauskis, J, Shelton, T, Shelton, C, Frick, J, Gastier-Foster, JM, Gerken, M, Leraas, KM, Ramirez, NC, Wise, L, Zmuda, E, Tarvin, K, Saller, C, Park, YS, Button, M, Carvalho, AL, Reis, RM, Matsushita, MM, Lucchesi, F, de Oliveira, AT, Le, X, Paklina, O, Setdikova, G, Lee, J-H, Bennett, J, Iacocca, M, Huelsenbeck-Dill, L, Potapova, CO, Voronina, O, Liu, O, Fulidou, V, Cates, C, Sharp, A, Behera, M, Force, S, Khuri, F, Owonikoko, T, Pickens, A, Ramalingam, S, Sica, G, Dinjens, W, van Nistelrooij, A, Wijnhoven, B, Sandusky, G, Stepa, S, Juhl, IH, Zornig, C, Kwon, SY, Kelsen, D, Kim, GHK, Bartlett, J, Parfitt, J, Chetty, R, Darling, G, Knox, J, Wong, R, El-Zimaity, H, Liu, G, Boussioutas, A, Park, DY, Kemp, R, Carlotti, CG, da Cunha Tirapelli, DP, Saggioro, FP, Sankarankutty, AK, Noushmehr, H, dos Santos, JS, Trevisan, FA, Eschbacher, J, Dubina, M, Mozgovoy, E, Carey, F, Chalmers, S, Forgie, I, Godwin, A, Reilly, C, Madan, R, Naima, Z, Ferrer-Torres, D, Rathmell, WK, Dhir, R, Luketich, J, Ajani, JA, Janjigian, Y, Tang, L, Cheong, J-H, Chudamani, S, Liu, J, Lolla, L, Naresh, R, Pihl, T, Sun, Q, Wan, Y, Wu, Y, Demchok, JA, Ferguson, ML, Shaw, KRM, sheth, M, Tarnuzzer, R, Wang, Z, Hutter, CM, and Sofia, HJ

Abstract

Oesophageal cancers are prominent worldwide; however, there are few targeted therapies and survival rates for these cancers remain dismal. Here we performed a comprehensive molecular analysis of 164 carcinomas of the oesophagus derived from Western and Eastern populations. Beyond known histopathological and epidemiologic distinctions, molecular features differentiated oesophageal squamous cell carcinomas from oesophageal adenocarcinomas. Oesophageal squamous cell carcinomas resembled squamous carcinomas of other organs more than they did oesophageal adenocarcinomas. Our analyses identified three molecular subclasses of oesophageal squamous cell carcinomas, but none showed evidence for an aetiological role of human papillomavirus. Squamous cell carcinomas showed frequent genomic amplifications of CCND1 and SOX2 and/or TP63, whereas ERBB2, VEGFA and GATA4 and GATA6 were more commonly amplified in adenocarcinomas. Oesophageal adenocarcinomas strongly resembled the chromosomally unstable variant of gastric adenocarcinoma, suggesting that these cancers could be considered a single disease entity. However, some molecular features, including DNA hypermethylation, occurred disproportionally in oesophageal adenocarcinomas. These data provide a framework to facilitate more rational categorization of these tumours and a foundation for new therapies.

Published
2017

30. Nivolumab (NIVO) in patients (pts) with advanced (adv) chemotherapy-refractory (CT-Rx) esophagogastric (EG) cancer according to microsatellite instability (MSI) status: checkmate 032

Author

Ott, P.A., primary, Le, D.T., additional, Kim, J.W., additional, Ascierto, P.A., additional, Sharma, P., additional, Bono, P., additional, Peltola, K., additional, Jäger, D., additional, Evans, T.R.J., additional, de Braud, F., additional, Chau, I., additional, Bendell, J.C., additional, Tschaika, M., additional, Harbison, C.T., additional, Zhao, H., additional, Calvo, E., additional, and Janjigian, Y., additional

Published
2017
Full Text
View/download PDF

39. Prognostic significance of human epidermal growth factor-2 (HER2) in advanced gastric cancer: A U.S. and European international collaborative analysis.

Author

Shah, M. A., primary, Janjigian, Y. Y., additional, Pauligk, C., additional, Werner, D., additional, Kelsen, D. P., additional, Jaeger, E., additional, Altmannsberger, H., additional, Robinson, E., additional, Tang, L. H., additional, Barbashina, V. V., additional, and Al-Batran, S., additional

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results